Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: INDICATIONS AND USAGE Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. US FDA label
Use: INDICATIONS & USAGE Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. US FDA label
Use: INDICATIONS AND USAGE In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the… US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Dispersible tablet: 60 mg/30 mg/150 mg, 75 mg/50 mg/150 mg
- Syrup: 250 mg/5 mL Suspension (Pyzather), Rifampicin 200 mg/5 mL Suspension (Fampisec), Isoniazid 200 mg/5 mL
Registered products in the Philippines
3 products registered with the Food and Drug Administration (FDA) Philippines list Isoniazid + Pyrazinamide + Rifampicin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products3
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Akurit Z KidRifampicin + Isoniazid + Pyrazinamide | 60 mg/30 mg/150 mg Dispersible TabletAIu/LDPE Strip x 6's Box of 90's | RxVAT-exempt | Lupin Ltd.India | Lupin Philippines Inc | DRP-6189 | Mar 19, 2028 | |
HRZ Pedia DTRifampicin + Isoniazid + Pyrazinamide | 75 mg/50 mg/150 mg Dispersible TabletAlu/Alu Strip Pack x 28's (Box of 84's) | RxVAT-exempt | Oxalis LabsIndia | UNILAB, Inc. | DRP-12569 | Sep 6, 2027 | |
Tri Pedia KitPyrazinamide 250 mg/ 5 mL Suspension, Rifampicin 200 mg/ 5 mL Suspension, Isoniazid 200 mg/ 5 mL Syrup | Each kit contains: Pyrazinamide 250 mg/ 5 mL Suspension (Pyzather), Rifampicin 200 mg/ 5 mL Suspension (Fampisec), Isoniazid 200 mg/ 5 mL Syrup (Bacciter Forte)Each kit contains:; Pyrazinamide – Amber Glass Bottle x 120 mL (Box of 2's); Rifampicin – Amber Glass Bottle x 120 mL (Box of 1's); Isoniazid – Amber Glass Bottle x 120 mL (Box of 1's) | RxVAT-exempt | San Marino Laboratories CorporationPhilippines | — | DRP-9395 | Apr 7, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| 50 mg isoniazid + 75 mg rifampicin + 150 mg pyrazinamide dispersible fixed-dose combination tablet (pediatric) | ₱8.75 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed
These are government procurement and reimbursement references, not retail prices. Sources:
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Isoniazid + Rifampicin + Pyrazinamide |
| PNF listing | Oral: 50 mg + 75 mg + 150 mg dispersible fixed dose combination tablet (pediatric)Restrictions: List B: in vivo bioequivalence studies required (PNF code B) |
| PhilHealth GAMOT | Yes (listed since October 13, 2026) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .

